Ann Dermatol.  2014 Feb;26(1):141-143. 10.5021/ad.2014.26.1.141.

Prominent Alopetic Lesions of Lichenoid Drug Eruption Treated with Topical Tacrolimus

• Cho HK
• Lee SY

• KMID: 2265722
• DOI: http://doi.org/10.5021/ad.2014.26.1.141

Abstract

No abstract available.

MeSH Terms

Drug Eruptions*
Tacrolimus*
Tacrolimus

Figure

• 

  Fig. 1 Large violaceous flat plaque on the forehead and small parts of scalp (A), and violaceous polygonal shaped flat papules on the back (B) were observed on initial visit. Two weeks later, scalp involvement progressed to alopetic lesions on frontal scalp (C), vertex (D) and parietal scalp (E). On microscopic examination, necrotic epidermal keratinocytes, lichenoid cellular infiltration of lymphocytes, histiocytes (G: H&E, ×40), and a few eosinophils in the papillary dermis (H: H&E, ×400) were observed. After 8 weeks' application of 0.03% topical tacrolimus and discontinuation of ethambtol, alopetic skin lesions improved (F) than before (E).

Reference

1. Na CH, Seo HD, Chung BS, Shin BS. A case of lichenoid drug eruption with whole body and oral mucosal involvement caused by antituberculosis drugs. Korean J Dermatol. 2008; 46:1145–1148.

2. Chang KY, Park HJ, Lim YS, Choi HY, Myung KB. Clinical study and skin tests of patients with drug eruptions. Korean J Dermatol. 1998; 36:997–1004.

3. Powell ML, Ehrlich A, Belsito DV. Lichenoid drug eruption to salsalate. J Am Acad Dermatol. 2001; 45:616–619.

4. Eom SC, Chae YS, Suh KS, Kim ST. The clinical features of lichenoid drug eruption and the histopathologic differentiation between lichenoid drug eruption and lichen planus. Korean J Dermatol. 1994; 32:1019–1025.

5. Lozada-Nur FI, Sroussi HY. Tacrolimus powder in Orabase 0.1% for the treatment of oral lichen planus and oral lichenoid lesions: an open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102:744–749.